Evidence map›Paper›PMID 37810217›Full record

ArticleiScience2023

Factor V Leiden, estrogen, and multimorbidity association with venous thromboembolism in a British-South Asian cohort.

Emma F Magavern, Genes & Health Research Team, Damian Smedley, Mark J Caulfield

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Primary care diagnosed multimorbidity and risk of venous thromboembolism in Sweden.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  2. International journal of molecular sciences · 2025
    Article
  3. Review
  4. Review
  5. Factor V Leiden (R506Q), Prothrombin G20210A, and MTHFR C677T Variants and Thrombophilia in Qatar Biobank Participants: A Case Control Study.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Article
  6. Review
  7. Multimorbidity and Venous Thromboembolism: Epidemiological Evidence, Pathophysiology, Prophylactic and Therapeutic Anticoagulation Efficacy, Safety, and Difficulties. A Review.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Emma F MagavernWilliam Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Genes & Health Research Team
Damian SmedleyWilliam Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK.
Mark J CaulfieldWilliam Harvey Research Institute, Queen Mary University of London, London EC1M 6BQ, UK.
William Harvey Research Institute · GBQueen Mary University of London · GB

Funding

Medical Research Council MC_EX_MR/M009203/1Medical Research Council MC_PC_14089Medical Research Council MR/M009203/1Wellcome Trust 210561/Z/18/Z
6 · The paper itself

Abstract

Multimorbidity, estrogen use, and Factor V Leiden (FVL) are known independent risk factors for venous thromboembolism (VTE). This cross-sectional analysis of women in the Genes & Health British-South Asian cohort (N 20,048) linked the

Indexed as

Cardiovascular medicineClinical endocrinologyPublic health

Identifiers

PMID37810217
PMCPMC10550715
OpenAlexW4386314802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.